Advocacy for Better Dialysis
Dialysis PATIENTS Act: Yea.
Fresenius supports legislation to modernize the healthcare system and provide dialysis patients the opportunity for value-based, integrated care, vs. fee for service.
Dialysis PATIENTS Act: Nay
Non-profit dialysis company DCI and a Montana social worker discuss why they believe the act is NOT in patients’ best interests and would benefit only large dialysis companies.
New Act Could Expand Access to Telemedicine for Home Dialysis
CHRONIC Care Act would expand the originating sites for monthly clinical assessments to include freestanding dialysis facilities and patients’ homes, and lift geographic limits, starting in 2019. Home dialysis patients would still need a face-to-face visit with a nephrologist at least once every 3 months.
Beam Me Up, Dialyzors
Does telehealth work in dialysis? We don’t know yet, but an expert group met in Vienna, Austria to discuss the idea.
Kidney Health Initiative Involves Consumers
This public (FDA)/private (ASN) partnership obtains patient input throughout the lifecycle of approving new medical devices, including how patients can influence design, help to plan and implement clinical trials, and impact regulatory decisions.
In the Ides of March: National Kidney Month and World Kidney Day
Dr. Alok Agarwhal’s blog post focuses on the role of the US obesity pandemic in driving diabetes, high blood pressure—and chronic kidney disease.
How to Change “Adequate” Dialysis to Optimal
Adequate dialysis could change to optimal dialysis with one word: from payment per dialysis treatment to payment per treatment hour.
From the Patient Perspective.
Understanding the role of patients’ belief systems can guide medical professionals to help develop patient-centered, personalized treatment plans.
Let’s Hear it for the Patients!
When dialysis patients partner in research, their “experiential” knowledge is valuable and meaningful.
HDU critiques NIPRO needles in letter to FDA
Home Dialyzors United members know dialysis needles—they use them several times a week. The group challenged the “substantial equivalence” determination of NIPRO needles this month for a variety of reasons in a letter to the FDA. See the NIPRO response below.